Last reviewed · How we verify

PAI HOLDINGS PHARM — Portfolio Competitive Intelligence Brief

PAI HOLDINGS PHARM pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fortaz Ceftazidime marketed Third-generation cephalosporin Bacterial cell wall Metabolic 1985-01-01
Fortaz CEFTAZIDIME marketed ceftazidime Metabolic 1985-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abbott · 1 shared drug class
  2. Centre Hospitalier Universitaire de Besancon · 1 shared drug class
  3. Dr. Damon Scales · 1 shared drug class
  4. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 shared drug class
  5. Kamuzu University of Health Sciences · 1 shared drug class
  6. Korea United Pharm. Inc. · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. Murdoch Childrens Research Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PAI HOLDINGS PHARM:

Cite this brief

Drug Landscape (2026). PAI HOLDINGS PHARM — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pai-holdings-pharm. Accessed 2026-05-16.

Related